Clinical Trial Update: Safety and Tolerability of 200mg and 100mg of Venofer Administered to Hemodialysis(HD) Patients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the safety and tolerability of two iron sucrose doses (100 mg and 200 mg) given to hemodialysis patients has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• VENOFER (Iron sucrose)

Snippet

Sponsor: American Regent, Inc. | Conditions: Hemodialysis | Phase 4 | Status: COMPLETED